Arrowstreet Capital Limited Partnership Purchases 559,190 Shares of IQVIA Holdings Inc. $IQV

Arrowstreet Capital Limited Partnership raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 193.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 848,771 shares of the medical research company’s stock after purchasing an additional 559,190 shares during the quarter. Arrowstreet Capital Limited Partnership owned 0.50% of IQVIA worth $133,758,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Everpar Advisors LLC grew its position in IQVIA by 4.6% during the second quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock valued at $221,000 after buying an additional 62 shares during the period. Private Trust Co. NA boosted its stake in shares of IQVIA by 12.5% during the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after acquiring an additional 67 shares during the last quarter. Independent Advisor Alliance grew its position in shares of IQVIA by 4.2% during the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock valued at $318,000 after acquiring an additional 72 shares during the period. Penserra Capital Management LLC increased its stake in shares of IQVIA by 10.3% in the 2nd quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock worth $151,000 after purchasing an additional 90 shares in the last quarter. Finally, Forte Capital LLC ADV lifted its position in IQVIA by 0.3% during the second quarter. Forte Capital LLC ADV now owns 26,809 shares of the medical research company’s stock valued at $4,225,000 after purchasing an additional 92 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.60% of the stock is currently owned by company insiders.

IQVIA Stock Performance

NYSE:IQV opened at $225.76 on Wednesday. The company has a market cap of $38.45 billion, a price-to-earnings ratio of 30.97, a PEG ratio of 2.56 and a beta of 1.37. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $234.29. The stock’s 50 day simple moving average is $211.67 and its two-hundred day simple moving average is $185.28. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the subject of a number of analyst reports. Stifel Nicolaus upped their price target on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Friday, November 28th. Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the stock from $195.00 to $225.00 in a research note on Tuesday, September 9th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $265.00 target price (up previously from $235.00) on shares of IQVIA in a report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $241.44.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.